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Abstract 
 
Background/Aim. Preeclampsia (PE) belongs to the group of 
hypertensive disorders in pregnancy with the global average inci-
dence of 2.16%. It is considered as one of the leading causes of 
maternal and neonatal morbidity and mortality worldwide. The 
goal of this study was to assess the potential association between 
Val158Met catechol-o-methyltransferase (COMT), tumor necro-
sis factor-alpha (TNF-α) -857 C>T, tumor necrosis factor recep-
tor 1 (TNFR1) 36 A>G, interleukin-1alpha (IL-1α) 4845 G>T 
and interleukin-10 (IL-10) -1082 A>G polymorphisms and risk 
of early-onset preeclampsia (PE) and its complications. Meth-
ods. The study included 47 early-onset PE patients, which were 
grouped by disease severity and by size for gestational age and 47 
control cases. The Val158Met polymorphism was genotyped by 
polymerase chain reaction – restriction fragment length poly-
morphism (PCR-RFLP) analysis and inflammatory cytokine 
polymorphisms by the Sanger sequencing method. Results. The 
COMT Met allele as well as IL-1α T showed a protective role, 
decreasing the risk of early-onset PE after age and body mass in-
dex (BMI) adjustments. The detected interactions between the 
COMT Met and IL-10 A alleles, as well as between the COMT 
Met and TNF-α T alleles were insignificant after age and BMI 
adjustments. Conclusion.  COMT and IL-1α may be used as 
candidate genes for early-onset PE and its severe form and small 
for gestational age (SGA) complications. 
 
Key words:  




Uvod/Cilj. Preeklampsija pripada grupi hipertenzivnih 
poremećaja u trudnoći sa prosečnom incidencom od 2,16% i 
predstavlja jedan od vodećih uzroka morbiditeta i mortaliteta 
majki i novorođenčadi širom sveta. Cilj ove studije bio je da se 
ispita potecijalna povezanost između polimorfizma Val158Met 
katehol-O-metiltransferaze (COMT), faktor nekroze tumora-
alfa (TNF-α) -857 C>T, receptora 1 za faktor nekroze tumora 
(TNFR1) 36 A>G, interleukin-1 alfa (IL-1α) 4845 G>T i 
interleukin-10 (IL-10) –1082 A>G sa rizikom od pojave rane 
preeklampsije (PE) i njenih komplikacija. Metode. Ova studija 
obuhvatila je 47 bolesnica sa ranom PE, grupisanih prema 
težini oboljenja i prema veličini za odgovarajuću gestacionu 
starost, i 47 zdravih osoba. Polimorfizam Val158Met je 
genotipiziran analizom polymerase chain reaction – restriction 
fragment lenght polymorphism (PCR-RFLP), a polimorfizam 
inflamatornih citokina Sangerovom metodom sekvencioniranja. 
Rezultati. Aleli COMT Met i IL-1α T pokazali su protektivnu 
ulogu, smanjujući rizik rane PE nakon korekcije za starost i 
indeks telesne mase (BMI). Uočena interakcija između alela 
COMT Met i IL-10 A, kao i između alela COMT Met i TNF-α 
T nije bila statistički značajna nakon korekcije za starost i BMI. 
Zaključak. COMT i IL-1α se mogu koristiti kao geni kandidati 
za otkrivanje rane PE i njenih komplikacija, teškog oblika rane 
PE i PE sa zastojem u rastu. 
 
Ključne reči: 
comt protein, humani, citokini; preeklampsija; 
polimorfizam, genski. 
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Introduction 
Preeclampsia (PE) belongs to the group of 
hypertensive disorders in pregnancy with  global average 
incidence of 2.16%. It is considered as one of the leading 
causes of maternal and neonatal morbidity and mortality 
worldwide 1–3. Special attention should be paid to the early 
and severe form of PE, due to its correlation with a very 
high morbidity rate and a frequent occurrence of serious 
health complications 2, 4. 
The mechanism that initiates PE development is still 
unknown. The hypothesis is that combined over-expressed 
inflammatory response and angiogenic imbalance potentially 
cause an endothelial dysfunction 5. By analyzing epidemiolo-
gical data, it has been emphasized that genetic factors are 
one of the main risk factors for PE development, and nume-
rous candidate gene studies and linkage analyses have been 
carried out in this area 6. 
Recently, one of the genes whose expression showed to 
have potential as a candidate gene for PE and could be con-
nected with angiogenic imbalance is the COMT gene 7. 
COMT is among the major enzymes responsible for the inac-
tivation of catechol-estrogens, which play an important role 
in pregnancy management and fetal development 8. Different 
studies showed a correlation between the Val158Met COMT 
polymorphism and increased risk of PE in different patient 
groups 9. A more detailed investigation showed that fetal 
Val158Met COMT polymorphism was correlating with inc-
reased risk of PE, and maternal Val158Met COMT 
polymorphism showed a protective role 10. Furthermore, in 
line with the theory of excessive inflammatory response, se-
veral polymorphisms of inflammatory cytokines showed to 
be associated with PE 11–13. 
Recently we demonstrated that material COMT Met-
Met genotype was associated with decreased risk of early-
onset PE including its severe form as well as risk of small-
for-gestational-age (SGA) complicating PE 14. In contination 
of this study we investigated examine the potential correlati-
on between the Val158Met COMT, TNF-α -857 C>T, 
TNFR1 36 A>G, IL-1α 4845 G>T and IL-10 -1082 A>G 
polymorphisms and the risk of early-onset PE, the risk of a 
severe form of early-onset PE and risk of SGA complicating 
early-onset PE. Furthermore, the investigation included the 
assessment of potential interaction between associating 
polymorphisms in order to determine their potential 
synergistic or antagonistic effect. 
Methods 
Subjects 
The study was conducted at the Clinic of Gynecology 
and Obstetrics, Clinical Centre of Serbia, Belgrade, in the pe-
riod between September 2012 and December 2013. The offici-
al approval for this study was obtained from the Ethics Com-
mittee of the Clinical Centre of Serbia. All patients and control 
subjects were informed beforehand about this study and they 
provided their written informed consent to participate. 
The study included two groups of participants: the gro-
up of 47 early-onset PE patients and the control group of 47 
healthy cases. The early-onset PE group was divided into 
two subgroups: severe early-onset PE of 33 patients and mild 
early-onset PE of 14 patients. Based on the second criterion, 
all 47 early-onset PE patients were divided into two subgro-
ups: appropriate-for-gestational-age (AGA) subgroup with 
12 patients and SGA subgroup with 35 patients. 
PE, early-onset PE and severe PE were defined according 
to the American College of Obstetricians and Gynecologists 
Task Force on Hypertension in Pregnancy 15. SGA and AGA 
were defined according to the national birth weight distributi-
on of the Serbian population 16. The excluding criteria were 
any of the following: pregnant women with known abnormal 
fetal karyotype or chromosomal abnormalities, multi-fetal ges-
tation, gestational hypertension without proteinuria, chronic 
hypertension, diabetes mellitus, cardiovascular disease, auto-
immune disease and renal disease. 
The control subjects were defined as healthy singleton 
pregnancies, having come to the Clinical Centre of Serbia for 
delivery, and delivering a healthy neonate at term (37 weeks of 
gestation or more) without medical or obstetric complications. 
Antenatal care was provided according to hospital gui-
delines and protocols. One aliquot of analyzed 
ethylenediaminetetraacetic acid (EDTA) whole blood was 
kept frozen on -70°C for deoxyribonucleic acid (DNA) 
extraction and genotyping. At delivery, the type of delivery 
was recorded; gestational age was calculated; birth weight 
was measured, and the Apgar score was assessed. 
DNA preparation and genotyping 
Isolation of genomic DNA from 200 µL of peripheral 
blood was done with the commercial kit for isolating genomic 
DNA (Roche Diagnostics), in accordance with the manufactu-
rer's instructions. The detection of mutation presence in the 
gene for inflammatory cytokines and Val158Met COMT was 
performed by a polymerase (PCR) chain reaction amplification 
of DNA. The amplification was carried out in a PCR instru-
ment (Termocycler-in) GeneAmp PCR System 9700 (Applied 
Biosystems). The product of PCR reactions for inflammatory 
cytokine polymorphism was than digested by EXOsap-IT 
enzyme. The Sanger sequencing method was used to analyze 
the expected polymorphism by the Genetic Analyzer Applied 
Biosystem 3130. Sequences were analyzed in the Software 
Sequencing Analysis 5.2 with a 36 cm capillary and polymer 
POP7. The product of PCR reactions for COMT 
polymorphism was digested by enzyme NlaIII (Hin1II Thermo 
SCENTIFIC). Electrophoretic separation was performed on 
2.5% agarose gel, containing ethidium bromide. After digesti-
on the enzyme fragments were visualized under ultraviolet 
light on transillumination (Wilber Lourmat). 
Statistical analysis 
General clinical characteristics between cases and con-
trols were compared using Student’s t-tests or the Wilcoxon 
rank sum test where appropriate. Genotype frequencies were 
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Table 1  




n = 47, ґ ± SD 
Early-onset PE 
n = 47, ґ ± SD (p)  
Severe early-onset PE 
n = 33, ґ ± SD (p) 
Mild early-onset PE 
n =14, ґ ± SD (p) 
Early-onset PE SGA 
n = 35, ґ ± SD (p) 
Early-onset PEAGA 
n = 12, ґ ± SD (p) 
Age (years) 29.44 ± 4.49 32.14 ± 5.52 (0.009767) 
32.45 ±  5.22 
(0.007997) 
31.42 ± 6.3 
(0.2244) 
32.06 ± 6.09 
(0.03021) 
32.41 ± 3.55 
(0.03643) 
Gestational age (days) 275 ± 9 225 ± 28 (1.346 × 10-14) 
218 ± 23 
(3.142 × 10-15) 
241 ± 33 
(2.398 × 10-5) 
219 ± 24 
(5.357 × 10-14) 
240 ± 34 
(2.119 × 10-6) 
BMI (kg/m2) 24.16 ± 4.11 27.77 ± 3.93 (0.0002266) 
27.9 ± 4.25 
(0.0007854) 
27.46 ± 3.18 
(0.01384) 
27.0 ± 3.37 
(0.003876) 
30.03 ± 4.71 
(0.0007481) 
Systolic  BP (mmHg) 108.62 ± 9.9 162.98 ± 18.61 (3.456 × 10-13) 
171.36 ± 15.07 
(1.037 × 10-11) 
143.21 ± 8.23 
(1.758 × 10-7) 
163.57 ± 18.92 
(8.828 × 10-12) 
161.25 ± 18.35 
(4.39 × 10-7) 
Diastolic BP (mmHg) 70.17 ± 8.5 104.36 ± 11.68 (3.898 × 10-13) 
109.24 ± 9.36 
(9.147 × 10-12) 
92.86 ± 8.02 
(3.333 × 10-7) 
104.57 ± 11.14 
(7.54 × 10-12) 
103.75 ± 13.67 
(8.559 × 10-7) 
Proteinuria (g/24 h) / 3.74 ± 4.05 4.59 ± 4.41 1.73 ± 2.0 4.31 ± 4.12 2.07 ± 3.49 
Birth weight (g) 3340.24 ± 445.28 1511.3 ± 784.2 (1.853 × 10-13) 
1304.5 ± 536.2 
(1.918 × 10-13) 
1998.6 ± 1050.8 
(8.639 × 10-5) 
1206.3 ± 450.3 
(7.715 × 10-14) 
2400.8 ± 886.5 
(0.0005678) 
PE – preeclampsia; BMI – body mass index; SGA – small for gestational age; AGA – appropriate for gestational age;  
BP – blood pressure. 
Table 2 
Testing for Hardy-Weinberg Equilibrium (HWE) 
HWE in the control group  
(n = 47) 
Deviation from HWE (D) χ2 p 
COMT 0.032 2.1942 0.3338 
IL-1α 0.174 0.805 0.6686 
IL-10 0.214 0.0474 1 
TNF-α 0.215 0.0686 1 
TNFRI -0.219 0.0504 1 
IL-1α – interleukin-1 alpha; IL-10 – interleukin-10; TNF-α – tumor necrosis factor-
alpha; TNFRI – tumor necrosis factor receptor type I; COMT – catechol-o-
methyltransferase. 
tested against theoretical Hardy-Weinberg equilibrium (HWE) 
by χ2 contingency table analysis (degree of freedom = 2). Alle-
le and genotype frequencies were compared between all cases 
of PE and their controls by contingency tables or by the Fis-
her’s exact probability test, and odds ratios (OR) and 95% 
confidence intervals (CI) were computed. The frequency of 
homozygote for the common allele was considered as the refe-
rence for comparisons (OR = 1). Under a dominant model and 
a rare allele frequency of 0.34, our study sample had a power 
1-β = 0.78 to detect a genetic effect resulting in an OR = 0.2 at 
a type I error of 0.05. Power calculations were performed 
using the online tool Genetic Power Calculator 17. 
The polymorphisms individually associated with PE 
(with p < 0.05 as entry criteria) were included in logistic re-
gression models to test for joint multi-locus association with 
PE, both unadjusted and adjusted for clinical co-variables. 
All the computation was done in R language and envi-
ronment, version 3.1.0 18. 
Results 
Clinical characterization 
As shown in the previous study 14 significant differen-
ces were observed between early-onset PE patients and the 
control group in maternal age, body mass index (BMI), 
systolic and diastolic blood pressure (BP) and in gestational 
age at delivery. There was a significantly higher risk of SGA 
neonate delivery in patients with early-onset PE (Table 1). 
Deviataion from Hardy-Weinberg equlibrium (HWE) – D 
values for interleukin-10 (IL-10), tumor necrosis factor-alpha 
(TNF-α) and tumor necrosis factor receptor type I (TNFRI) 
were significant in investigated loci. In contrast, genotypes 
for COMT and interleukin-1 alpha (IL-1α) in the investiga-
ted population respectively comply with the HWE proporti-
ons (Table 2). 
COMT Val158Met genotyping 
The Met allele decreased the risk for early-onset PE de-
velopment and early-onset PE SGA development. There was 
no statistically significant difference between the mild and 
severe form of early-onset PE (Table 3). The strongest 
statistically significant influence was noticed in the allele re-
cessive model. The MetMet genotype was decreasing the 
risk of early-onset PE and PE complications (Table 4). 
IL-1α4845 G>T genotyping 
T allele decreased the risk for early-onset PE development, 
severe early-onset PE and early-onset PE SGA development 
(Table 5). GT and TT genotypes were associated with decreased 
risk of early-onset PE and PE complications (Table 6). 
IL-10-1082 A>G, TNF-α -857 C>T and TNFR1 36 
A>G genotyping 
There was no statistically significant association 
between IL -1082 A>G, TNF-α -857 C>T or TNFR1 36 
A>G genotype and early-onset PE, severe early-onset PE or 
early-onset PE SGA observed (p > 0.05). 
Multinomial logistic regression ґ 
Older age and increased BMI significantly led to early-
onset PE development. Even after age and BMI correction, a  
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Table 3 







Severe early-onset PE 
OR (n) 
Mild early-onset PE 
OR (n) 
Early-onset PE SGA 
OR (n) 
Early-onset PE AGA 
OR (n) 
Val (37) (52) (37) (15) (39) (13) 
Met (57) 0.526(42)* 0.511(29) 0.565(13) 0.518(31)** 0.552(11) 
*p = 0.04057; **p = 0.0411;  
SGA – small for gestational age; AGA – appropriate for gestational age; BP – blood pressure; COMT – catechol-o-methyltransferase;  
n – number. 
 
Table 4 








Severe early-onset PE 
OR (n) 
Mild early-onset PE 
OR (n) 
Early-onset PE SGA 
OR (n) 
Early-onset PE AGA 
OR (n) 
Val-Val and 
Met-Val (27) (39) (27) (12) (29) (10) 
Met-Met  (20) 0.281 (8)* 0.304 (6)** 0.229 (2) 0.284 (6)*** 0.275 (2) 
*p = 0.01235, Fisher exact test; **p = 0.02928; ***p = 0.01732;  
SGA – small for gestational age; AGA – appropriate for gestational age; BP – blood pressure; COMT – catechol-o-methyltransferase;  
n – number. 
 
Table 5  








Severe early-onset PE 
OR (n) 
Mild early-onset PE 
OR (n) 
Early-onset PE SGA 
OR (n) 
Early-onset PE AGA 
OR (n) 
G (62) (83) (58) (25) (61) (22) 
T (32) 0.259 (11)* 0.269 (8)** 0.235 (3)*** 0.288 (9)**** 0.178 (2)***** 
*p = 0.0004281; **p = 0.0016; ***p = 0.0173; ****p = 0.0019; *****p = 0.012 
SGA – small for gestational age; AGA – appropriate for gestational age; OR – odds ratio; n – number. 
 
Table 6 
The interleukin-1 alpha (IL-1α) allele dominant model in the investigated group of early-onset preeclampsia (PE) patients 








Severe early-onset PE 
OR (n) 
Mild early-onset PE 
OR (n) 
Early-onset PE SGA 
OR (n) 
Early-onset PE AGA 
OR (n) 
GG (22) (38) (26) (12) (27) (11) 
GT and TT (25) 0.212 (9)* 0.241 (7)** 0.151 (2)*** 0.265 (8)**** 0.082 (1)***** 
*p = 0.001123; **p = 0.00532; ***p = 0.0136; ****p = 0.0067; *****p = 0.0075;  





Multinomial logistic regression including age, body mass index (BMI), COMT and interleukin-1 alpha (IL-1α) polymorphisms 
Variable / polymorphism  Early-onset PE adjusted OR (95% CI) Early-onset PE p-value 
Age (years) 1.122(1.015–1.253) 0.030064 
BMI (kg/m2) 1.134(1.133–1.568) 0.000876 
COMT (AR model) 0.308(0.091–0.960) 0.047627 
IL-1α (AD model) 0.167(0.048–0.508) 0.002620 
PE – preeclampsia; OR – odds ratio; CI – confidence intervals; BMI – body mass index;  
IL-1α – interleukin-1 alpha; COMT – catechol-o-methyltransferase. 
 
statistically significant association between Val158COMT or 
IL-1α polymorphism and early-onset PE development still 
remained. 
COMT-Met homozygous was showing a protective role 
by reducing the risk for early-onset PE development 3.2 ti-
mes, as well as IL-1αT allele, of which one dose reduced the 
risk for early-onset PE development for almost six times 
(Table 7). 
Interactions between Val158Met COMT, TNF-α -857 
C>T, TNFR1 36 A>G, IL-1α 4845 G>T and IL-10 -1082 
A>G polymorphisms 
The presence of COMT Met allele and TNF-α T allele 
additionally increased the risk for early-onset PE develop-
ment 2.765-fold in comparison to the simple multiplying of 
both OR. After age and BMI adjustment, this interaction be-
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Table 8 





BMI and age 
p – unadjusted 





BMI and age 
p – adjusted 






COMT (Met) : IL-1α (T) 0.618 NS 0.509 NS 0.190 
COMT (Met):IL-10 (A) 0.369 0.0647 0.357 0.0827 0.937 
COMT(Met):TNF-α(T) 2.765 0.0491 1.703 NS 0.490 
IL-1α(T):IL-10(A) 0.799 NS 1.046 NS 0.159 
IL-1α(T):TNF-α(T) 1.948 NS 2.486 NS 0.371 
IL-10(A):TNF-α(T) 1.724 NS 1.470 NS 1.239 
BMI – body mass index; IL-1α – interleukin-1 alpha; IL-10 – interleukin-10; TNF-α – tumor necrosis factor-
alpha; COMT – catechol-o-methyltransferase; OR – odds ratio. 
 
 
came statistically insignificant. The interaction between 
COMT Met allele and IL-10 A allele was close to the statis-
tical level of significance, uncorrected as well as corrected 
for age and BMI. Combined OR was significantly different 
(almost three times higher) in comparison to the multiple of 
those two OR, leading to the conclusion that IL-10 A allele 
presence reduced the protective effect of COMT Met allele 
2.71-fold (Table 8). 
Discussion 
Many genes and their polymorphisms have been 
examined in order to detect the potential markers for high-
risk pregnancies 19, 20. Due to the most recent highlights in 
the theories of ‘excessive inflammation’ and ‘angiogenic im-
balance’ as the potential causes of PE, there is a dilemma 
whether the polymorphisms of genes associated with these 
could be a potential cause of PE development 5. 
Recently, the animal COMT mice knockout model has 
shown to be useful in clarifying the significance of decreased 
COMT expression in PE 7. Even though this study was 
revolutionary in the field of PE genetic models investigation, 
it was clearly limited with the absence of differentiation 
between maternal and fetal low COMT activity. Our study 
confirmed the protective role of low maternal COMT 
activity. The explanation could be found in a hypothesis that 
Hill et al. 10 proposed, which considered decreased maternal 
COMT activity as a protective role by stimulating the pla-
centa to produce 2-ME. Placental low COMT activity is the 
key contributor for PE development. We are further suppor-
ting our finding with the fact that our control group is on 
HWE for COMT genotype. 
Regarding the potential association of COMT allele dis-
tribution and early-onset PE complicated with SGA, our 
study showed that MetMet decreased the risk of early-onset 
PE SGA for more than 3.5 times. To the contrary, Sata et 
al. 21 showed that patients with homozygous COMT-L alleles 
had a 2.98 times higher risk of low birth weight (< 2,500 
g) 20. It is concluded that lower COMT activity may lead to 
the accumulation of catechol estrogens, and thus, cause 
oxidative DNA damage which may be associated with 
SGA 22. These explanations could be applied to fetal low 
COMT activity and our suggestion is that low maternal 
COMT activity could show a protective role allowing higher 
fetal COMT activity. Further studies are needed to investiga-
te these contradictory data. 
Another group of polymorphisms that were included in 
the scope of our investigation are inflammatory cytokine ge-
ne polymorphisms: TNF-α -857 C>T, TNFR1 36 A>G, IL-
1α 4845 G>T and IL-10 -1082 A>G. Haggerty et al. 11 showed 
that IL-1α 4845 GG genotype significantly increased the PE 
risk (black OR 11,6; 95% CI 1,5-89,3; white OR 1,7; 95% CI 
0,7–3,9). The combination of TNF-α -857C>T and TNFR1 36 
A>G polymorphisms leads to 2.26-fold times increased risk of 
PE. The effect was even stronger in their joint presence with 
IL-1α 4845 G>T polymorphism, which together were associa-
ted with higher than 4 times higher risk of PE development 
(OR = 4.13; CI95: 2.16 – 7.89; p = 0.00002) 12. The most 
frequently investigated polymorphism was IL-10 -1082 A>G. 
However, a meta-analysis performed by Lee et al. 13 showed a 
statistically insignificant association, after excluding the studi-
es where the distribution of control subjects was deviating 
from HWE. In our study, we could only find a statistically sig-
nificant association between IL-1α 4845 G>T polymorphism 
and the risk of early-onset PE, severe early-onset PE and 
early-onset PE with SGA. The potential reason could be the 
limited number of patients included in this study, as well as a 
potentially inappropriate control population selection for these 
polymorphisms, described by significant deviation from HWE 
for TNF-α, TNFR1and IL-10 in the control group. 
Regarding the potential of the IL-1α 4845 G>T 
polymorphism to do the risk stratification of PE, to our 
knowledge this is the first study investigating this topic. Signi-
ficant differences in the IL-1α 4845 G>T allele distribution 
between the mild and severe form of PE could be identified. 
We also showed the association between the IL-1α 4845 G>T 
polymorphism and early-onset PE associated with SGA. 
For the statistically significant loci, adjustments for age 
and BMI was made in a multivariate logistic regression 
analysis. It is important to underline that we confirmed 
previously published data about positive association between 
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age or BMI with PE development 23. Even after age, BMI 
and other statistically significant polymorphism adjustments, 
each of the two polymorphisms still showed a statistically si-
gnificant association with early-onset PE development. 
Finally, we investigated the interactions between the 
previously mentioned polymorphisms and their association 
with early-onset PE, which is to our knowledge the first 
study investigating this topic. The allele model showed a 
statistically significant interaction between the COMT Met 
allele and TNF-α T allele which significance after age and 
BMI adjustments disappeared. Secondly, the interaction 
between COMT Met and IL-10 A alleles, unadjusted as well 
as age and BMI adjusted, were on the level of statistical sig-
nificance. Further studies are needed in order to investigate 
this suggestion in the larger population size. 
The main shortcoming of our study was the limited 
number of investigated patients, as we were primarily focu-
sed on difficult cases of early-onset PE (33 severe early-
onset PE patients in comparison to 47 early-onset PE patients 
in total) with a mean systolic BP 162.98 ± 18.61 mmHg and 
diastolic BP 104.36 ± 11.68 mmHg. Further studies with a 
bigger sample size of early-onset PE patients should be con-
ducted in order to investigate the significance of a potential 
interaction between COMT and inflammatory cytokines 
polymorphisms. 
Conclusion 
We showed that the distribution of COMT as well as 
IL-1α alleles between early-onset PE patients and control su-
bjects was different, particularly between SGA early-onset 
PE patients and respected control subjects. The COMT Met 
allele as well as IL-1α T showed a protective role, decreasing 
the risk of early-onset PE after age and BMI adjustments. In-
teraction between COMT Met and IL-1α T did not show any 
statistically significance. Statistical significance was obser-
ved in interaction between the COMT Met and IL-10 A alle-
les, but it was not any more statistically significant after age 
and BMI adjustments. Interaction between the COMT Met 
and TNF-α T alleles were close to level of significance, both 
before and after age and BMI adjustments. 
COMT and IL-1α may be used as candidate genes for 
detection of high-risk patients for development of early-onset 
PE and its severe form and SGA complications. 
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